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Abstract 
Alzheimer’s disease (AD) is a chronic neurodegenerative disease and is the sixth leading cause of 
death in the United States with approximately 5.5 million Americans diagnosed with it. The 
neuropathological hallmark includes extracellular senile plaques and intraneuronal neurofibrillary 
tangles. Recent GWAS studies have identified genes associated with AD, and have revealed 
several classes of genes implicated in disease pathogenesis. In particular, three general pathways 
associated with an increased risk of AD included:  1) cholesterol metabolism, innate immune 
system, and the membrane trafficking. Our lab has focused on intracellular trafficking as it relates 
to the processing of amyloid precursor protein (APP), the precursor protein for the Aβ peptide—a 
critical component of the senile plaque.  Much is still unknown about the intracellular itinerary of 
APP, and the cellular location of Aβ production. Here, I describe the use of click-chemistry applied 
to an APP construct to further study APP processing.  In addition, I describe work that I did to 
develop a microfluidic system to enable visualizing APP processing within the unique 
cytoarchitecture of primary neurons. Microfluidics helps in isolating the soma and axon to 
understand APP processing in these specific compartments.  
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CHAPTER 1 
Introduction 
Alzheimer’s disease is a chronic neurodegenerative disease and is the sixth leading cause of death 
in the United States with approximately 5.5 million Americans diagnosed with it 1. The major 
pathological hallmark for Alzheimer’s is accumulation of insoluble deposits of amyloid-beta (Aβ) 
peptide. GWAS studies for AD showed various factors of which the genes in the intracellular 
pathway of APP has gained the most attention2 . This peptide is obtained by the sequential 
proteolytic cleavage of amyloid precursor protein (APP) 3. One of the challenges in understanding 
this disease has been in elucidating the trafficking and processing of Aβ. To understand this 
problem Aβ has been engineering by click-labelling 4 to visualize the trafficking.  
1.1 Proteolytic processing of APP 
The amyloid-beta (Aβ) peptide is made up of 37-43 amino acids, obtained by proteolytic 
cleavage of amyloid precursor protein (APP). APP is a type-I oriented membrane protein 
with its carboxyl (C) terminal in the cytosol and the amino (N) terminal in the lumen. APP 
is proteolytically processed at several different subcellular locations and is targeted by 
three different proteases – alpha (α), beta (β) and gamma (γ) secretases 3.  
APP can undergo two processes- the amyloidogenic pathway that leads to the generation 
of Aβ and the anti-amyloidogenic pathway that prevents the generation of Aβ (figure 1.1)3. 
The amyloidogenic pathway produces Aβ by the consecutive action of β and γ secretase. 
The β-secretase activity initiates Aβ generation by shedding the ectodomain of APP 
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(APPsβ) and generates the C-terminal (βCTF) that is cleaved by the γ -secretase. Following 
the γ-secretase cleavage, Aβ is found in the extracellular fluids like plasma and 
cerebrospinal fluid 3.  
In the anti-amyloidogenic pathway, APP is cleaved nearly in the middle of the Aβ region 
by α-secretase giving rise to α-CTF, followed by γ-secretase cleavage resulting in the 
generation of a small 3kDa peptide called p3. Apart from p3 and Aβ, γ-secretase also 
generates APP intracellular domain (AICD) that is involved in nuclear signaling 3.  
   
Figure-1.1: Anti-amyloidogenic and amyloidogenic processing of APP 
 
1.2 Cellular trafficking of APP 
In non-polarized mammalian cell lines, APP transits from endoplasmic reticulum (ER) to 
the plasma member (PM). During this transit, APP is post-translationally modified. in the 
Golgi apparatus and the trans-Golgi network (TGN). Membrane APP that hasn’t been shed 
(due to alpha-secretase cleavage) is internalized due to the presence of the “YENPTY” 
motif near the C-terminus. Following this, APP is sent to endosomes and a fraction of the 
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endocytosed molecules is recycled to the cell surface, recycled to the TGN, or trafficked 
down the lysosomal pathway 3.  
  
Figure-1.2.a: Cellular trafficking of APP in non-polarized cells. 
 
In neurons, the trafficking is complicated due to the various compartments in the neurons- 
soma, axon and dendrites. APP trafficking in the neuronal soma is similar to that of the 
non-neuronal cell, that is, it transports from ER to Golgi and TGN. After leaving the TGN, 
APP is transported to axons and dendrites in post Golgi transport vesicles. APP delivery to 
axons makes use of fast axonal transport system but there are several theories with respect 
to its processing 3. 
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Figure-1.2.b:APP and secretases transport in neurons.  
 
 
1.3 APP processing in axons  
APP processing in neurons is still not understood due to the complex system of 
compartmentalizing and transport. Two models had been proposed as to the processing of 
APP in axons. One model postulated by Muresan et.al. 2009, states that APP is processed 
in the soma and the cleaved products gets sorted into axons. This is supported by finding 
that the endocytic sorting pathway for the β secretase: BACE-1, is limited largely to the 
soma. But a recent paper by Thinakaran et.al.2015 found BACE-1 enriched in axons5.   
Another model proposes local processing in axons/synapses with extracellular APP 
fragments. This model is supported by the evidence that there is colocalization of 
processing enzymes together with APP in vesicles and evidence that synaptic activity in 
vivo increases due to endocytosis-dependent Aβ release in the brain. From these finding it 
can be deduced that Aβ secretion is dependent on synaptic activity and endocytosis, 
implicating synapses as the site of processing and secretion 6. 
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A recent paper by Niederst et.al 2015, used compartmentalized culture system to study the 
processing. A microfluidic system was used to study Aβ generation. The samples from the 
axonal compartment was collected and Aβ measured. The Aβ fragments were identified 
using immunoassay. The amount of protein secreted per axon was calculated as by 
multiplying the volumes from both soma and axons with APP fragment concentration and 
divided by number of axons per chamber. To estimate the number of molecules secreted 
per axon, Avogadro’s number was multiplied with the fragment concentration. Total 
axonal concentration was calculated by subtracting the APP amount from the somal 
chamber. They compared mouse and human hippocampal neurons and found the result to 
be consistent. They determined that about 70-80% of APP is being processed in the soma6.  
One of the concerns is to understand whether APP fragments are endocytosis- independent 
or dependent. They found that axonal Aβ generation is dependent on endocytosis sorting 
and is a major pathway. This was found by using dynasore, a dynamin inhibitor, reduced 
the amount of axonal APP suggesting that it is endocytic dependent. 6. 
So far, the sorting of APP fragments was understood but not for full length-APP (FL-APP). 
They found that FL-APP can enter the axon in endocytosis independent pathway 6.
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a b c  
Figure 1.3.a: a) Comparison of APP and it’s fragments in soma versus axon 
                         b) Graph indicating endocytosis as major pathway for axonal Aβ generation 
                         c) Graph indicating that FL-APP sorting is endocytosis independent 
                  
                               
They also found that there are multiple pathways for axonal sorting of APP, Aβ and 
BACE1 sorting 6. 
  
Figure 1.3.b: Colocalization of APP, Aβ and BACE1 with subcellular markers 
 
One of the key questions that remains unanswered is the site of Aβ generation and it’s 
trafficking in the neurons. To understand, Das et.al 2013, designed an assay called 
OptiCAB to find the sites of interaction of APP and BACE1 to better understand the first 
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cleavage event leading to Aβ generation. As with the previous study, they found soma to 
be region of maximum interaction of APP and BACE-1. They found that APP and BACE-
1 was co-transported in axons and can interact during transit. Immobile APP and BACE-1 
particles were found near the dendrites and presynaptic boutons 7.  
The result from this paper indicate that APP and BACE-1 interact in both endocytosis and 
biosynthetic compartments, in recycling endosomes distributed throughout the neuronal 
processes and in Golgi-derived vesicles in which they are co-transported. It also implicates 
recycling microdomains (dendritic spines and presynapses) as important sites of APP and 
BACE-1 convergence. Also show that APP endocytosed from the plasma membrane enters 
late endosomes or lysosomes 7. 
 
   
Figure 1.3.c: Colocalization of APP-BACE1 in dendrites with recycling endosomes (TfR & 
Rab11), early endosomes (Rab5), lysosome (LAMP1), Golgi (NPYss) 
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Figure 1.3.d: Colocalization of APP-BACE1 in axons and presynaptic boutons with recycling 
endosomes (TfR & Rab11), early endosomes (Rab5), lysosome (LAMP1), Golgi (NPYss) 
 
These studies show an indirect relation to the possible subcellular location of Aβ and it’s 
trafficking is still unknown. To address this issue, APP was click-labelled in the Aβ region 
to help in identifying it’s trafficking. This works consists of validation of the clicked-
labelled Aβ and fabrication of microfluidic devices to help in neuronal studies. 
 
1.4 Microfluidics 
Microfluidics is the science and technology of systems that process and manipulate small 
amounts of fluids in a geometrically constrained scale. It provides several advantages in 
analysis as it exploits both it’s small scale and the characteristics of fluids in the micro-
channels. Some of these advantages include decreased cost of manufacture, use ad disposal, 
decreased time of analysis, reduced consumption of reagent and analytes, reduced 
production of potentially harmful byproducts, increased separation efficiency and 
portability and decreased weight and volume 8. It has uses in molecular analysis, 
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biodefense, molecular biology, microelectronics, clinical diagnostics and drug 
development 9.   
Fluid dynamics inside the microfluidics gives a unique advantage to them. The Reynold’s 
number in micro-channels is less than 2000 and flow is laminar. In these conditions gravity 
is less important, and the surface forces become dominant to influence the flow. The 
mixing of fluids in this system is only by diffusion. Electro-osmotic flow can be observed 
for charged fluids 10. 
   
Figure 1.4.a: Laminar flow seen in micro-channels  
Most microfluidic systems are carried out in polymers like poly(dimethylsiloaxane) or 
PDMS. The properties of PDMS has various advantages that makes it favorable for 
microfluidics. Some of these properties include its elastomeric nature, it’s optical 
transparent and can absorb wavelength in 240-1100 nm range, it acts as an insulator, it’s 
non-toxic and biocompatible. It is permeable to gases and compatible with water and polar 
solvents 10. 
The surface chemistry of PDMS can be changed easily to exploit it for our uses. PDMS is 
hydrophobic, that consists of repeating units of –O-Si(CH3)2. When it is exposed to oxygen, 
air, plasma or UV, there is loss of the methyl group to make PDMS hydrophilic. The 
hydrophilic nature is reversible and to prevent it from reverting back, PDMS should be 
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kept in contact with polar solvents. Due to it’s hydrophobicity, PDMS can be reversibly 
bond onto glass or irreversible bond after plasma/UV treatment 10. 
Microfluidic system made of PDMS are fabricated using soft lithography technique. This 
includes using rapid prototyping for device design using AutoCAD, followed by replica 
molding of PDMS 11. 
             
Figure 1.4.b: Fabrication process of microfluidic devices made from PDMS 
 
Due to these various advantages of microfluidic devices made from PDMS, it has several 
applications for neuroscience. It has been used  for neuron cell culture, neuron 
manipulation, neural stem differentiation, neuropharmacology, neuro electrophysiology 
and neuron biosensors 12. In this regard, a multicompartment microfluidic device was 
designed specifically for neuroscience research. This device is an improvement over the 
Campenot chambers. The device has been extensively used for the study of Alzheimer’s 
disease. These devices were used to isolate single axons and manipulate different regions 
of the neurons 13.   
11 
 
                   
Figure 1.4.c: Images of micro-channels in microfluidic devices cultured with neurons  
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CHAPTER 2 
Validation of click-labelled APP in primary cells 
2.1 Experimental procedure 
Primary cells- N2a, were used to test the click-labelled APP molecular tool. The cells were 
transfected with APP-mClover DNA and APP-Amber-mClover DNA. Following transfections, 
the cells were fixed and stained with antibodies. The cells were then imaged using confocal 
microscopy and analyzed using Imaris. The analysis was based on colocalization of APP with 
various subcellular. The total percent of colocalization of click-labelled and mClover tagged 
APP was compared with wild-type APP-mClover. 
 
2.2 Experimental protocols 
2.2.1 Cell passaging and plating- 
i. Media is aspirated from the flask and 3ml of PBS is added.  
ii. PBS is aspirated and 2ml of 0.05% trypsin is added and incubated for 3 minutes.  
iii. 8ml of media is added to stop the trypsin action and the cell count is taken.  
iv. The cells are resuspended and 150uL of the cells are added to each well in the quadrant 
dishes. ~17,000 N2a cells/well is added. 
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2.2.2 Transfection- 
i. Label two tubes per condition, one for DNA and one for lipofectamine 
ii. Add opti-MEM to each tube 
iii. Add lipofectamine to the lipo tube and incubate for 5 minutes at room temperature. 
iv. Add DNA to the DNA tube. 
v. Mix DNA with lipofectamine and incubate for 20 minutes at room temperature. 
vi. Remove 50ul of media per well in quadrant dishes and add 50uL of DNA-lipofectamine 
mixture.  
vii. Incubate at 37oC for 6-8 hours. Remove transfection reagents. 
viii. Add media with unnatural amino acids (CPK+HEPES).  
ix. Incubate at 37oC overnight. 
 
2.2.3 Fixing and permeabilizing cells- 
i. Media is removed from the wells. 
ii. Wash with 1xPBS. 
iii. Add cold 4% PFA and incubate for 10 minutes. Wash with 1xPBS, thrice. 
iv. Permeabilize cells with 0.3% triton X-100 for 10 minutes at room temperature.  
v. Wash with 1x PBS. 
 
2.2.4 Antibody staining- 
i. Add blocking agent to each well. 
ii. Allow blocking for 30 minutes.
14 
 
iii. For N2a cells plated on cover slips, transfer the coverslips to flat bottom box (place wet 
tissues on either side to keep the box moist) 
iv. Add primary antibody. Leave it for 30-45 minutes. Wash with 1x PBS, thrice. 
v. Add secondary antibody. Leave for 30-45 minutes at room temperature. 
vi. Wash with 1x PBS, thrice. 
vii. For N2a cells plated on coverslips, add 10uL droplets of Gelvitol on a glass slide. Place 
each cover slip on the droplets, so that the cells are in contact with Gelvitol (place inverted 
with respect to plating). Allow the coverslip to get fixed on the slide. (About 1 hour). 
Blocking agent for N2a- 1x PBS + 1% Saponin + 10% goat serum 
 
2.2.5 Imaging – 
The cells were imaged in Nikon A1R confocal microscopy. 100x resolution oil immersion were 
used to visualize the cells. The wavelength of laser lights differed for different antibodies. The 
antibodies of APP were colocalized with Golgi, lysosome, and endosomal subcellular markers. A 
Z-stack image was captured. 
 
2.2.5 Analysis – 
The colocalization analysis was carried out using the Imaris software. The colocalization 
analysis was carried out by picking the overlapping signal from APP and subcellular marker. The 
percent APP was calculated by the APP intensity in a subcellular site divided by the total APP 
15 
 
intensity in cell. The percent APP was calculated for APP-Amber-mClover N2a and WT APP-
mClover N2a. 
2.3 Results and discussion 
2.3.1 Selection of subcellular antibodies: 
The subcellular organelles involved in endocytic pathway of APP processing include early 
endosomes, Golgi and trans-Golgi network and late endosome/ Lysosomes 3, 14. Various 
antibodies were tested to get the best result for colocalization. EEA1 is an early endosomal 
marker used for the current work. EEA1 is essential for early endosomal membrane fusion and 
trafficking. Rab7 was used for late endosome and lysosomal marker. It is a Ras-related protein 
and is important in late endocytic pathway. Golgin97 was used as the subcellular marker against 
trans-Golgi network. Golgin97 is known to help maintain trans-Golgi integrity and function by 
localization of TGN resident proteins.   
  
Figure 2.3.1a: EEA1 antibody to identify early endosome
16 
 
     
Figure 2.3.1b: Golgin97 antibody to identify trans-Golgi network 
 
   
Figure 2.3.1c: Rab7 antibody to identify late endosome / lysosome 
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2.3.2 Imaging: 
The cells were imaged in oil immersion at 100X resolution. The Z-stack of the cells were 
obtained. The colocalized images were captured. 
 
 
 
 
Figure 2.3.2a: N2a cells stained with EEA1 and colocalization of mClover signal with EEA1 
 
 
 
 
 
Figure 2.3.2a: N2a cells stained with Rab7 and colocalization of mClover signal with Rab7 
 
 
 
 
Figure 2.3.2a: N2a cells stained with Golgin97 and colocalization of mClover signal with Golgin97
APP-WT-mClover EEA1 merge 
merge APP-WT-mClover Rab7XP 
merge Golgin97 
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2.3.3 Analysis: 
The percent APP was calculated by the APP intensity in a subcellular site divided by the total 
APP intensity in cell. The percent APP was calculated for APP-Amber-mClover N2a and WT 
APP-mClover N2a. 
   
Figure 2.3.3a: Comparison of percent colocalization of APP with EEA1 in click-labelled and 
WT cells 
 
   
Figure 2.3.3b: Comparison of percent colocalization of APP with Rab7 in click-labelled and 
WT cells 
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Figure 2.3.3c: Comparison of percent colocalization of APP with Golgin97 in click-labelled and 
WT cells 
The colocalization of click-labelled and WT APP-mClover was carried out and the percent APP 
was found. We expect a co-occurrence with the sub-cellular markers and not a correlation. The 
percent APP colocalized in both the cells are not very different indicating the click-labelling 
doesn’t alter the trafficking. This shows that the tool is useful in visualizing APP trafficking.
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CHAPTER 3 
Fabrication of microfluidic device to study APP trafficking in neurons 
The neurons are a complex cell that have various organelles that are highly compartmentalized. 
It consists of axons, dendrites and soma. The trafficking of proteins in these structures takes 
place with the help of highly specialized trafficking organelles. Hence the trafficking of APP can 
be complex in neurons and requires unique devices to study each part of a neuron. Microfluidics 
can be exploited to study the trafficking of APP in neurons. These devices can fluidically isolate 
soma and axons. This helps us in understanding the trafficking and processing of APP in axons. 
This also allows us to manipulate the axons alone. Using this device, it is possible to click-label 
axons alone or click label the synapses to visualize the APP trafficking. 
 
3.1 Experiment procedure: 
Microfluidic device was designed to isolate single axons in order to study APP trafficking. It 
involves design, fabrication, testing and trouble-shooting of the device. The device is an open 
channel type and was fabricated using soft lithography technique. 
The device fluidically isolates the soma and the axon. The neurons are plated in the somal 
chamber and the axons extend into the micro-channels and reach the axonal chamber. A volume 
difference is maintained between the chambers which ensures that the flow is from soma to the 
axon chamber. When the volume in both the chambers is kept equal, there is no flow between the 
chambers creating a fluidic isolation.   
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3.2 Experimental protocols 
3.2.1 Microfluidic device fabrication 
1. Mask design- The mask was designed using AutoCAD 2017 software 15. The mask was 
designed following the mask design rules from Stanford Microfluidic Foundry 16. The mask 
design consists of two layers- micro-channels layer and chamber layer.  
 
              
Figure 3.2.1a: First layer of the mask consisting of micro-channels and alignment marks 
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Figure 3.2.1b: Second layer of the mask consisting of main channels  
 
    
Figure 3.2.1c: Final mask design with both the layers 
 
2. Device specifications- The micro-channels are 500um long, 5um wide, 10um deep and have 
10um spacing between channels. The total channel count per device is approximately 300. The 
current mask design consists of four pair of devices (eight devices in a mask). The space between 
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two adjacent devices is 2.5 mm. The main channels are 5 mm in length, 5mm in breadth and 100 
um in depth 17.     
              
Figure 3.2.2a: Microfluidic device dimensions- main channels and micro-channels 
 
 Table 3.1: Microfluidic device dimensions 
 
 
 
 
 
   
  
   
3. Mold fabrication- The mold was fabricated on a 3-inch silicon wafer. The mold was 
fabricated in-house. The protocol for fabrication was followed from the paper by Park et.al. 2006.  
Soft lithography technique was used for fabrication 15. The fabrication steps are as follows 18:
Micro-channels Length  500 um 
Width 5 um 
Depth 10 um 
Spacing 10 um 
Main channels Length 5 mm 
Width 5 mm 
Depth 100 um 
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i. The 3-inch wafer is cleaned with acetone, isopropyl alcohol and sterile water. It is dried 
with nitrogen. 
ii. The wafer is placed in the spin coater. Approximately 1ml of SU8-3010 photoresist is 
added. It is spun at 3000 rpm for 32s at the rate of 300 rpm/s to obtain a height of 10um. 
iii. The wafer is soft baked at 95oC for 3 minutes. 
iv. Wafer is exposed through a high-resolution transparency mask containing the first layer 
with micro-channels at 200 mJ/cm2. 
v. Post-exposure baked the wafer for 60 seconds at 65oC and 2 minutes at 95oC. 
vi. Developed with SU8 developer for 3 minutes. 
vii. A second layer of photoresist- SU8-2050 was spun at 1750 rpm for 32 seconds at the 
rate of 300 rpm/s to get a height of 100um. 
viii. Soft baked at 65oC for 5 minutes and at 95oC for 20 minutes. 
ix. It was exposed through a high-resolution transparency mask containing the second 
layer with man channels at 240 mJ/cm2. 
x. Post-exposure baked at 65oC for 2 minutes and at 95oC for 10 minutes. 
xi. Developed with SU8 developer for 10 minutes. 
xii. Wafer was cleaned with isopropyl alcohol and water, followed by drying with nitrogen 
gas. The cleaned mold dimensions were measured using the profilometer. 
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Figure 3.2.3: Microfluidic device mold fabricated on Si wafer using soft lithography  
 
4. PDMS device fabrication- The PDMS device was made by replica molding technique. The 
following steps were carried out: 
i. PDMS and its activator are weighed out in a 10:1 ratio in a disposable container and mixed 
thoroughly. Approximately 25g of PDMS was used for the devices to achieve a thickness 
of about 5-7 mm. 
ii. The PDMS is poured onto the mold. It is placed in vacuum desiccator for 30 minutes to 
remove any air bubbles. Any remaining bubbles are removed by using pressurized air/ 
razor blade. 
iii. The PDMS is cured in an oven at 70oC for more than 3 hours. 
iv. The PDMS is removed from the mold and cut into individual devices. 
v. 6 mm holes were punched into main channels. 
5.  Cleaning the devices- The devices are dynamically washed with 70% ethanol thrice, 
followed by washing with sterile water. Any additional particles stuck on the PDMS surface was 
removed using scotch tape. 
6.  Bonding- PDMS can be bond to glass slide reversibly or irreversibly 18. The devices were 
bond reversibly by placing the device with the channels facing the glass and pressing it gently. The 
device is bond to the glass by Van der Waal’s forces 11. It is bond irreversibly by UV exposure. 
The PDMS device (the channels facing up) and glass slide are exposed to UV for 5 minutes and 
bond together18. 
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7. Coating- The bonded devices are coated with poly-D-lysine (PDL) and Laminin 19. 1ml of 
0.1mg/ml of PDL is mixed with 35ug of Laminin. This mixture is added to the main channels and 
incubated at 37oC overnight. The solution is removed and washed with sterile water.  
 
3.2.2 Cell passaging and plating- 
Primary hippocampal cells are obtained from rat brain. [Courtesy of Dr. Steven Mennerick]  
i. 1:1 dilution of neurons in media is made. 
ii. 200uL of diluted cells is added to dishes coated with PDL+Laminin and incubated at 
37oC overnight. 
iii. In the microfluidic device, 120uL of media is added to one well (axonal chamber) and 
150uL of diluted cells is added to the other well. This maintains a flow of media so that 
neurons move close to the micro-channels. 
iv. The devices are incubated at 37oC overnight.    
3.2.3 Transfection- 
i. Label two tubes, one for DNA and one for lipofectamine 
ii. Add Lipofectamine and MEM+ to lipofectamine tube and mix. Incubate for 5 minutes at 
room temperature. 
iii. Add DNA and MEM+ to DNA tube and mix. 
iv. Mix DNA and lipofectamine tube and incubate for 20min at room temperature. 
v. Warm remaining MEM+ in incubator 
vi. Remove media from neurons with 10mL pipette and save for CPK addition 
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vii. Add 100ul prewarmed MEM+ to each dish 
viii. Add 100ul transfection reagents dropwise to each dish. Incubate for 6 hours 
ix. Aspirate transfection reagents + media 
x. Add conditioned media + CPK + HEPES (Conditioned media:CPK=100:1; CPK:HEPES 
= 5:1) 
xi. Incubate at 37oC overnight. 
MEM+ (1ml) = 1ml MEM+ 5uL APV + 2uL NBQX 
3.2.4 Fixing and permeabilizing cells- 
i. Media is removed from the wells. 
ii. Wash with 1xPBS. 
iii. Add cold 4% PFA + 4% sucrose and incubate for 10 minutes. Wash with 1xPBS, thrice. 
iv. Permeabilize cells with 0.3% triton X-100 for 10 minutes at room temperature.  
v. Wash with 1x PBS. 
3.2.5 Antibody staining- 
i. Add blocking agent to each well. 
ii. Allow blocking for 30 minutes. 
iii. Add primary antibody and incubate at 4oC overnight. 
iv. Wash with 1x PBS, thrice. 
v. Add secondary antibody. Leave for an hour at room temperature. 
vi. Wash with 1x PBS, thrice. 
vii. 1x PBS is added. 
Blocking agent for neurons - 1x PBS + 0.3% triton X-100 + 3% Bovine serum albumin
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3.2.6 Imaging- 
The device with neurons were imaged using confocal microscopy. The Nikon A1Rsi, a scanning 
confocal Microscopy at the Washington University Center for Cellular Imaging, was used for 
imaging the samples. The images were viewed through 10x and 20x objective in oil immersion.  
 
3.3 Results and discussion: 
3.3.1 Devices used: 
Four different devices were tested to see which device was compatible. We tested two 
commercial devices and two lab made devices.  
1. Devices from Xona Microfluidics - The microfluidic device is manufactured by Xona 
Microfluidics 18. The device consists of four chamber wells, two main channels and micro-
channels. It is a closed type. The device can be segregated into axonal and somal chamber. 
The dimensions of the device are as follows-  
i. Chamber wells are 5mm x 5mm, 8mm punched holes 
ii. Main channels are7 mm in length, 1.5 mm in width and 100uM in depth 
iii. Micro-channels are 500um in length, 5um in width, 3um in depth and 5um in 
spacing. 
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 Figure 3.3.1a: Microfluidic device from Xona 
2. Devices from Ananda devices- These microfluidic devices were manufactured from Ananda 
devices 20. It is a closed type of device and consists of somal and axonal chambers. The 
device consists of four chamber wells, two main channels and micro-channels. The 
dimensions of the device are as follows-  
i. Chamber wells are 5mm x 5mm, 4mm punch holes 
ii. Main channels are 5mm in length, 1.5 mm in width and 100uM in depth 
iii. Micro-channels are 500um in length, 5um in width, 30um in depth and 30um in 
spacing. 
   
 Figure 3.3.1b: Microfluidic device from Ananda
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3. Lab made devices- Two sets of devices were fabricated in the Institute of Material Science 
and Engineering at Washington University in St Louis. The device is an open type device 17.  
The device consists of two wells- somal and axonal wells, that are connected by micro-
channels. The dimensions of the device are as follows-  
i. Chamber wells are 5mm x 5mm, 6mm punch holes 
ii. Micro-channels are 500um in length, 5 um in width, 10um in spacing and 15/ 10 um 
in depth. 
            
Figure 3.3.1b: Lab made microfluidic devices  
 
      
3.3.2 Device comparison: 
1. Xona devices- The devices were easy to bond to the glass slides. The large punch holes 
gave an easy access to angle the pipette. The reversibly bonded devices were found 
to leak and the devices were UV bonded. The bonded devices were used to plate the 
neurons. It was seen that neuron survival was low and no neurons were found near 
the micro-channels. The devices could only be used a few times as it was difficult to 
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remove the cell debris in the main channels. Due to these disadvantages the device 
were not chosen to carry out any further studies. 
2. Ananda devices- The devices easily bond to glass slides and were not UV bonded as 
they were tightly sealed. The small punch holes made it difficult to angle the pipette 
tip close to micro-channels. There was an improved survival of the neurons in the 
somal chambers compared to that of Xona devices but very few neurons were found 
in the main channels and none were close to the micro-channels to extend axons. The 
devices were found to harden after a few uses and difficult to bond. Due to these 
disadvantages the device was not chosen to carry out any further studies. 
3. Lab-made devices (15um)- The lab made devices easily bond to the glass slides and the 
large punch holes made for an easy access to angle the micropipette close to micro-
channels. There was a significant increase in the neurons that survived in the wells. 
The neurons were growing close to the micro-channels and possible axon extension 
into the channels were seen. But the micro-channel walls were not straight and was 
difficult to segregate them. Due to these disadvantages the device was not chosen to 
carry out any further studies. 
4. Lab-made devices (10um)- The lab made devices easily bond to the glass slides and the 
large punch holes made for an easy access to angle the micropipette close to micro-
channels. There was a significant increase in the neurons that survived in the wells. 
The neurons were growing close to the micro-channels and axons were extending 
into the channels. This device was selected.
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3.3.3 Trouble-shooting: 
1. Micro-channels- The 15um devices had channels that were not straight and was difficult to 
segregate. To overcome this problem, the height of the micro-channels was reduced to 10um. 
This height reduced the strain on the walls and hence were straight.  
     
  Figure 3.3.3a: Micro-channels from 15um device with crooked walls 
      
Figure 3.3.3b: Micro-channels from 10um device with straight walls 
2. Cell debris- The micro-channels of 15um devices was blocked by cell debris. This prevented 
the axons from extending into the micro-channels. Addition of AraC with the media reduced the 
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cell debris. The angling of the micropipette slightly away from the micro-channels also reduces 
the cell debris clogging the channels.  
           
         Figure 3.3.3c: Micro-channels blocked with cell debris 
 
 
  
Figure 3.3.3d: Micro-channels with reduced cell debris
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3. Neuron survival- The devices coated with only PDL did not have any neurons surviving. 
The devices were coated with PDL and laminin, incubated at 37oC for 2 hours. These had 
very low survival rate. When the devices coated with PDL and laminin were incubated at 
37oC overnight the neurons survived. The neurons survive in the devices for 14 days. 
    
   Figure 3.3.3e: Wells with low neuron count 
 
 
    
   Figure 3.3.3e: Wells with high neuron count 
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4. Neurons growing underneath the channels- The axons were found to extend the neurons 
underneath the channels in reversibly bonded devices. When the devices were UV bonded to 
glass the axons were seen to grow only inside the channels. 
        
       Figure 3.3.3f: Axons growing underneath the channels 
 
       
      Figure 3.3.3g: Axons growing only in the channels
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3.3.4 Imaging: 
The neurons plated in the devices were healthy and can survive up to 14 days in vitro. 
The neurons that were 7 DIV were fixed, stained, and imaged. The neurons were stained 
with SMI-312 marker known to stain axons. It is directed against highly phosphorylated 
axonal epitopes of neurofilaments Heavy and Medium subunits. MAP2 marker was used 
to stain the soma.  A healthy number of neurons were seen in the somal chambers. The 
axonal chamber was free of debris establishing fluidic separation from the somal 
chamber. Axons were seen extending into the micro-channels.  
    
         Figure 3.3.4a: Parts of the microfluidic device 
 
SOMAL CHAMBER 
MICROCHANNELS 
AXONAL CHAMBER 
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Figure 3.3.4b: Neurons in the microfluidic device stained with neuronal markers 
    
             
Figure 3.3.4b: Axons seen extending into the micro-channels and absence of dendrites
SMI 312` MAP2 Merged 
SMI 312` MAP2 
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